We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
After the draft E9(R1) Addendum on estimands and sensitivity analysis in clinical trials was first introduced, one of the most frequently asked questions was whether the proposed framework was applicable to Oncology clinical trials and time-to-event endpoints. This webinar expands on how the estimand framework can help improve the way in which clinical trials are designed and planned, and how primary analyses and sensitivity analyses are appropriately conducted with an emphasis on the therapeutic area of Oncology and time-to event endpoints.
The webinar host is Kristina Bondareva, the Head of Biostatistics at OCT Clinical.
Learn more about OCT Clinical's biometrics services here: https://oct-clinicaltrials.com/services/biostatistics
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
